Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)

Slides:



Advertisements
Similar presentations
Stroke Care. What has been achieved so far and what still needs doing? Tony Rudd.
Advertisements

Evidence for Early Supported Discharge. Peter Langhorne Professor of Stroke Care University of Glasgow.
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
Thrombolysis for stroke in older people.
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
THROMBOLYSIS Alteplase: indications and contra-indications Dr Ken Fotherby, New Cross Hospital.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Target: Stroke Building on Success A national quality improvement initiative of the American Heart Association/American Stroke Association to improve.
EM TREATMENT OF ACUTE STROKE Progress, Problems, Politics William G. Barsan, M.D. University of Michigan.
Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.
Stroke Mark Sudlow Consultant and Senior Lecturer
Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA) July 2008.
Prophylaxis of Venous Thromboembolism
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Brain attack! Is it a Stroke? Dr Richard I Lindley Consultant Geriatrician Part-time Senior Lecturer
“ Remember that stroke patient you treated last night…” What to Expect following tPA Use in Acute Ischemic Stroke The INSTINCT Trial NIH / NINDS R01 NS
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
What neurologist may add to the care and cure of of stroke patients, or… Peter Sandercock Perugia December 2007 What is the place of the neurologist in.
Clinical diagnosis in the acute phase of stroke – quite a challenge! Peter Sandercock Edinburgh.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Stroke Units Southern Neurology. Definition of a stroke unit A stroke unit can be defined as a unit with dedicated stroke beds and a multidisciplinary.
SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.
Primary PCI Treatment of choice for Acute MI.
Supporting NHS Wales to Deliver World Class Healthcare All Wales Stroke Services Improvement Collaborative Learning Session One 21 st October 2009.
The third international stroke trial (IST-3) of rt-PA. Main Results II: IST3 in context of updated meta-analysis of the randomised trials. JM Wardlaw,
IST-3 – an imaging substudy Dr Ingrid Kane Clinical research fellow.
Consultant Neurologist,
The need for trials of i.v. thrombolysis in acute ischaemic stroke 10 th January 2008.
Interventions in Acute Ischemic Stroke: Strategies for the New Millennium For the next 25 minutes, we will spend sometime talking about Neuroimaging.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Stroke and the ED Kurian Thomas, MD Department of Neurology.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Rationale: Why do we still need a large trial? IST-3 The Third International Stroke Trial: National Coordinators’ Meeting 25 May 2005, Bologna Professor.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
Update on IST-3 and other trials. Or, ‘how the ECASS-3 results have helped re-launch IST-3!’ Professor Peter Sandercock, Co-chief investigator IST-3 collaborator’s.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
S afe I mplementation of T hrombolysis in S troke Slide presentation adapted from
The third international stroke trial (IST-3) effect of thrombolysis on outcomes at 18 months in 2348 patients in long-term follow- up cohort The IST3 collaborative.
RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.
Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009.
Third International Stroke Trial (IST-3): response to ECASS-3 results Professor Peter Sandercock, University of Edinburgh Collaborators Meeting Vienna.
Consent in acute stroke trials: a view from IST3 Peter Sandercock University of Edinburgh SRN Training Day Newcastle 25 th June 2008.
EXERCISE AFTER STROKE Specialist Instructor Training Course L3 Stroke: the first few days Prof. Gillian Mead Reader and Consultant The University of Edinburgh.
Stroke is a Medical Emergency. Face Arm Speech Test Helps public recognise symptoms of stroke; Can they smile? Does one side droop? Can they lift both.
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
IST-3: What are the implications for rt-PA therapy? Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC Lisbon 23rd.
IST-3: progress with the trial internationally and plans for the future Peter Sandercock Riunione Gruppo Italiano IST-3 Firenze 13 th February 2009.
Thrombolysis for acute ischaemic stroke Clinical
Thrombolysis: The Evidence Barry Moynihan Stroke Physician, St. George’s Hospital SITS/BASP Thrombolysis Nursing Training Day March 26 th 2012.
IST-3, SITS MOST ECASS-3 & DEFUSE Professor Peter Sandercock University of Edinburgh, UK ESC May 30 th 2007 Glasgow Competing interests:
Time Is Brain: Advanced Stroke Treatment Grahame C Gould, MD Jefferson Neurosurgical Associates at Main Line Health, Bryn Mawr Hospital Division of Neurovascular.
Brain waves or brain drain Interactive case discussion Dr Jenny Vaughan and Dr Richard Perry Charing Cross Hospital Hammersmith Hospital Imperial College.
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
ACUTE STROKE TREATMENT: An introduction Dec.2014
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
Dr Marc Randall Consultant Neurologist and Stroke Physician Honorary Senior Lecturer University Sheffield.
Medical Director PVHMC Stroke Center Financial disclosure:None
Baseline characteristics of the 3035 patients recruited in IST3
Setareh Omran, MD Vascular Neurology Fellow
Volume 379, Issue 9834, Pages (June 2012)
Jennifer E. Fugate, DO, Alejandro A. Rabinstein, MD 
Presentation transcript:

Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3) Dramatic recovery 4-5/5 power, now talking

How does thrombolysis work? Blood clots are a common cause of ischaemic stroke They are made up of fibrin polymers cross linked by factor X111 (end result of intrinsic and extrinsic coagulation pathway) Plasminogen activators Streptokinase recombinant tissue-type plasminogen activator PLASMINOGENPLASMIN FIBRIN Fibrin degradation products

Thrombolysis for acute ischaemic stroke Not routine therapy in Edinburgh (or most of UK) Why not? To help you understand why not, I will: Present the world data on thrombolysis Compare the situation with myocardial infarction Explain why it could be too expensive to deliver What we are doing about it

Acute brain attack Exclude: fits/migraine Hypo-hyperglycaemia Other metabolic causes CT Scan Exclude tumour /structural lesion Non-stroke pathology Confirmed ischaemic brain attack PICH, SAH, Subdural Exclude: intracranial bleed

Confirmed ischaemic brain attack TIA Are the symptoms/signs resolving rapidly? Yes No Are the symptoms/signs disabling? No Treat like TIA Yes Consider more intensive treatment

Thrombolysis: Acute Ischaemic Stroke Relatively short history - RCTs mid 80’s. Early decisions about agent and dose. NEJM 1995;333: rt-PA approved in North America for selected patients within 3 hours of stroke onset. Not approved in Europe. rt-PA use remains quite limited. ? administrative & organisational barriers. ? evidence not as persuasive as for AMI.

Thrombolytic Time Window: Acute MI Systematic review of 9 large RCTs involving 58,000 patients. Fibrinolytic Therapy Trialists’ Group. Lancet 1994;343: Sufficient statistical power to provide reliable estimates of: DURATION of time window. DECLINE in benefit over time.

Thrombolytic Time Window: Acute MI Fibrinolytic Therapy Trialists’ Group. Lancet 1994;343:

Data: Thrombolysis vs control ThrombolyticNumber of Number of Agent RCTs patients IV tPA (56%) IV SK (25%) IV UK (14%) IA Pro-UK (5%) Total * *9% of available MI data; data on 72 patients from ATLANTIS B not yet available.

Symptomatic ICH (fatal & non-fatal) All trials: –2.5% control versus 9.5% treatment. –70 additional ICHs for every 1000 treated (95% CI ; 2p< ) rt-PA trials only: –3% control versus 10% treatment. –73 additional ICHs for every 1000 treated (95% CI ; 2p< ) No significant heterogeneity noted.

Dead or dependent at end of follow-up All trials: –59% control vs 55% treatment (2p=0.003). –44 more patients alive and independent for every 1000 patients treated (95% CI ). rt-PA trials: –57% control vs 51% treatment (2p=0.002). –57 more patients alive and independent for every 1000 patients treated (95% CI ). Significant heterogeneity noted...

Dead or dependent at follow-up: randomisation within 3 hours IV SK vs control IV tPA vs control NINDS ECASS 1 ECASS 2 subtotal IV SK+asp vs asp TOTAL thrombolysis better thrombolysis worse 7 trials; 1168 patients

Absolute effect of thrombolysis for every 1000 patients treated: rt-PA Outcome hours hours ICH more (data not available) Dead 7 fewer - 43 more 61 fewer - 38 more Dead or fewer fewer dependent figures are 95% CI

Thrombolysis and living with unproven treatments Definite evidence of risk. Evidence of benefit - but which patients benefit most and which patients are most likely to be harmed? Answering this question may allow more patients to be effectively treated with increased certainty.

What remains unproven? The upper age limit. The latest time for effective treatment. The role of aspirin. The influence of stroke severity. The influence of CT scan appearance. The generalisability of thrombolysis and the organisation of acute stroke services in non- specialist centres. Long-term effect of thrombolysis.

The Third International Stroke Trial (IST-3) Main features Streamlined trial (to encourage participation) Time window of <6 hours from onset (realistic and evidence based) Recruitment started in the Western General Hospital and six other UK hospitals

Stroke IS an Emergency!  Stroke is a “Brain Attack”  Stroke is an emergency  “Time is Brain”

Future Stroke Treatment? 999 Nurse led Stroke Management process - Evaluation and Triage Within 3-6 Hrs?

The Stroke Team Ambulance Service Casualty Dept & ICU/ASU Radiology/Neuroradiology/ Physicians/Radiographers Neurology & Neurosurgery Pharmacy & Laboratory Rehabilitation Admissions Administration Public Relations/Community Education